Hunan Nucien Pharmaceutical Co Ltd
Hunan Nucien Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research and development, production, and sale of chemical drugs in China. The company also focuses on the research, development, production, and sales of antiviral drugs, including influenza and infectious disease prevention and treatment drugs, as well as medicines for anti-influenza, malignant tumors, cardiovascula… Read more
Hunan Nucien Pharmaceutical Co Ltd (688189) - Total Assets
Latest total assets as of June 2025: CN¥1.07 Billion CNY
Based on the latest financial reports, Hunan Nucien Pharmaceutical Co Ltd (688189) holds total assets worth CN¥1.07 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hunan Nucien Pharmaceutical Co Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Hunan Nucien Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hunan Nucien Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Hunan Nucien Pharmaceutical Co Ltd's total assets of CN¥1.07 Billion consist of 63.7% current assets and 36.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 40.1% |
| Accounts Receivable | CN¥195.60 Million | 16.0% |
| Inventory | CN¥61.17 Million | 5.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥220.50 Million | 18.0% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Hunan Nucien Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hunan Nucien Pharmaceutical Co Ltd's current assets represent 63.7% of total assets in 2024, an increase from 33.1% in 2016.
- Cash Position: Cash and equivalents constituted 40.1% of total assets in 2024, up from 17.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, a decrease from 20.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 18.0% of total assets.
Hunan Nucien Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Hunan Nucien Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Hunan Nucien Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Hunan Nucien Pharmaceutical Co Ltd generates 0.22x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Hunan Nucien Pharmaceutical Co Ltd is currently not profitable relative to its asset base.
Hunan Nucien Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.58 | 4.40 | 4.24 |
| Quick Ratio | 2.34 | 4.23 | 4.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥369.11 Million | CN¥ 845.47 Million | CN¥ 1.31 Billion |
Hunan Nucien Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Hunan Nucien Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.69 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -28.9% |
| Total Assets | CN¥1.22 Billion |
| Market Capitalization | $159.21 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hunan Nucien Pharmaceutical Co Ltd's assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hunan Nucien Pharmaceutical Co Ltd's assets decreased by 28.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hunan Nucien Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual total assets of Hunan Nucien Pharmaceutical Co Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.22 Billion | -28.90% |
| 2023-12-31 | CN¥1.72 Billion | -12.03% |
| 2022-12-31 | CN¥1.95 Billion | -8.27% |
| 2021-12-31 | CN¥2.13 Billion | +2.15% |
| 2020-12-31 | CN¥2.09 Billion | +154.79% |
| 2019-12-31 | CN¥818.72 Million | +17.62% |
| 2018-12-31 | CN¥696.05 Million | +15.52% |
| 2017-12-31 | CN¥602.53 Million | -1.95% |
| 2016-12-31 | CN¥614.53 Million | -- |